Equities research analysts expect Apricus Biosciences Inc (NASDAQ:APRI) to announce earnings per share of ($0.13) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Apricus Biosciences’ earnings. Apricus Biosciences posted earnings of ($0.04) per share in the same quarter last year, which indicates a negative year over year growth rate of 225%. The firm is scheduled to report its next earnings results on Monday, March 12th.
On average, analysts expect that Apricus Biosciences will report full year earnings of ($0.60) per share for the current year, with EPS estimates ranging from ($0.92) to ($0.28). For the next year, analysts anticipate that the business will report earnings of $1.28 per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that that provide coverage for Apricus Biosciences.
Apricus Biosciences (NASDAQ:APRI) last posted its earnings results on Thursday, November 2nd. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.15). During the same quarter last year, the firm earned ($0.19) EPS.
Apricus Biosciences (APRI) remained flat at $$1.82 during midday trading on Wednesday. 305,329 shares of the stock were exchanged, compared to its average volume of 147,494. The firm has a market cap of $27.68, a PE ratio of 3.14 and a beta of 0.44. Apricus Biosciences has a 1-year low of $0.86 and a 1-year high of $4.07.
About Apricus Biosciences
Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.